Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy

Description

30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.

Conditions

Gynecologic Cancer, Immunotherapy, Gut Microbiome

Study Overview

Study Details

Study overview

30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.

Pilot Feasibility Study of the Interplay Between the Host Gut Microbiome and Efficacy of Treatment for Advanced or Recurrent Gynecological Cancer Patients Receiving Immunotherapy

Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy

Condition
Gynecologic Cancer
Intervention / Treatment

-

Contacts and Locations

Orlando

AdventHealth Cancer Institute, Orlando, Florida, United States, 32804

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult females \> 18 years old
  • * Advanced or recurrent gynecological cancer patients from AHMG Advent Health Orlando Gynecologic Oncology Group
  • * Patients for whom an immunotherapy regimen has been ordered
  • * Patients unable to provide fecal specimens at three time points
  • * Patients unable to read or understand informed consent
  • * Taking medications that may affect gut microbiome:
  • * Proton pump inhibitors (PPIs)
  • * Metformin
  • * Antibiotics
  • * Laxatives
  • * Patients who are receiving investigational agent

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Viome,

Momchilo Vuyisich, PhD, PRINCIPAL_INVESTIGATOR, Viome Life Sciences

Study Record Dates

2024-06